CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
- €3.1 million financing led by new investor Clave Capital, with participation from existing investors
- Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout expected in mid-2027
Barcelona, Spain – 10 September 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, F.C.R. fund and supported by existing investors Inveready, CDTI Innvierte and Prous Institute for Biomedical Research.
